AbbVie Stock Price, News & Analysis (NYSE:ABBV)

$96.30 -0.17 (-0.18 %)
(As of 12/12/2017 04:00 PM ET)
Previous Close$96.47
Today's Range$94.76 - $96.69
52-Week Range$59.27 - $98.52
Volume4.20 million shs
Average Volume6.09 million shs
Market Capitalization$153.18 billion
P/E Ratio18.07
Dividend Yield2.67%
Beta1.52

About AbbVie (NYSE:ABBV)

AbbVie logoAbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:ABBV
CUSIP00287Y10
Phone847-932-7900

Debt

Debt-to-Equity Ratio5.08%
Current Ratio1.45%
Quick Ratio1.32%

Price-To-Earnings

Trailing P/E Ratio18.07
Forward P/E Ratio17.35
P/E Growth1.33

Sales & Book Value

Annual Sales$25.64 billion
Price / Sales6.00
Cash Flow$5.62 per share
Price / Cash17.15
Book Value$2.85 per share
Price / Book33.79

Profitability

Trailing EPS$4.11
Net Income$5.95 billion
Net Margins24.38%
Return on Equity153.80%
Return on Assets12.83%

Miscellaneous

Employees30,000
Outstanding Shares1,596,430,000

AbbVie (NYSE:ABBV) Frequently Asked Questions

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Friday, October 27th. Investors of record on Friday, January 12th will be paid a dividend of $0.71 per share on Thursday, February 15th. This represents a $2.84 dividend on an annualized basis and a yield of 2.95%. The ex-dividend date of this dividend is Thursday, January 11th. This is a boost from AbbVie's previous quarterly dividend of $0.64. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie announced that its Board of Directors has approved a share buyback plan on Sunday, April 9th 2017, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 5% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board believes its stock is undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) announced its quarterly earnings results on Friday, October, 27th. The company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.02. The business had revenue of $7 billion for the quarter, compared to analysts' expectations of $7 billion. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The business's quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.21 earnings per share. View AbbVie's Earnings History.

When will AbbVie make its next earnings announcement?

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, January, 26th 2018. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY18 earnings guidance on Friday, October, 27th. The company provided earnings per share (EPS) guidance of $6.37-6.57 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.59. AbbVie also updated its FY17 guidance to $5.53-5.55 EPS.

Where is AbbVie's stock going? Where will AbbVie's stock price be in 2017?

14 analysts have issued 1 year price objectives for AbbVie's shares. Their predictions range from $84.00 to $115.00. On average, they anticipate AbbVie's stock price to reach $99.77 in the next year. View Analyst Ratings for AbbVie.

What are Wall Street analysts saying about AbbVie stock?

Here are some recent quotes from research analysts about AbbVie stock:

  • 1. According to Zacks Investment Research, "AbbVie reported mixed Q3 results.  While earnings beat estimates, revenues came in line. Humira and Imbruvica kept up the strong performance. Meanwhile, AbbVie raised its earnings outlook for the year backed by a strong year-to-date performance.  Despite new competition, it raised its long-term target for Humira sales based on strong demand trends for the drug. Meanwhile, the past 2-3 months have been strong for the company as it presented promising data from several pivotal studies, gained regulatory approvals in the U.S., Europe, and Japan for its competitive HCV medicine Mavyret and FDA approval for the sixth indication for Imbrivica and settled its Humira patent disputes with Amgen. Also, several pivotal data readouts and regulatory milestones are expected in 2018. AbbVie’s shares have outperformed the industry this year so far. However, HCV sales continue to be hurt by intensifying competition." (11/1/2017)
  • 2. UBS AG analysts commented, "For other pipeline products, we already included appropriate risk-adj estimates and in some cases significant risk adj sales (Rova-T)," (9/25/2017)
  • 3. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)

Who are some of AbbVie's key competitors?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:

  • Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer (Age 63)
  • William J. Chase, Executive Vice President, Chief Financial Officer (Age 49)
  • Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer (Age 51)
  • Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary (Age 53)
  • Carlos Alban, Executive Vice President - Commercial Operations (Age 54)
  • Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer (Age 44)
  • Timothy J. Richmond, Senior Vice President - Human Resources (Age 50)
  • Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations (Age 53)
  • Robert A. Michael, Vice President, Controller (Age 46)
  • Robert J. Alpern M.D., Independent Director (Age 66)

Who owns AbbVie stock?

AbbVie's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (1.05%), Legal & General Group Plc (0.51%), Epoch Investment Partners Inc. (0.49%), Capital International Investors (0.49%), American International Group Inc. (0.48%) and Ameriprise Financial Inc. (0.45%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Who sold AbbVie stock? Who is selling AbbVie stock?

AbbVie's stock was sold by a variety of institutional investors in the last quarter, including Woodford Investment Management Ltd, Ameriprise Financial Inc., Janus Henderson Group PLC, Alyeska Investment Group L.P., Schroder Investment Management Group, Nordea Investment Management AB, Santa Barbara Asset Management LLC and Comerica Bank. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Who bought AbbVie stock? Who is buying AbbVie stock?

AbbVie's stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Capital International Investors, KBC Group NV, Assenagon Asset Management S.A., Canada Pension Plan Investment Board, APG Asset Management N.V., PGGM Investments and Artemis Investment Management LLP. View Insider Buying and Selling for AbbVie.

How do I buy AbbVie stock?

Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of AbbVie stock can currently be purchased for approximately $96.30.

How big of a company is AbbVie?

AbbVie has a market capitalization of $153.18 billion and generates $25.64 billion in revenue each year. The company earns $5.95 billion in net income (profit) each year or $4.11 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.


MarketBeat Community Rating for AbbVie (ABBV)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  638 (Vote Outperform)
Underperform Votes:  375 (Vote Underperform)
Total Votes:  1,013
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AbbVie (NYSE:ABBV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.612.612.502.38
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $93.41$92.41$77.61$70.13
Price Target Upside: 2.09% downside0.52% upside11.55% downside3.32% upside

AbbVie (NYSE:ABBV) Consensus Price Target History

Price Target History for AbbVie (NYSE:ABBV)

AbbVie (NYSE:ABBV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/5/2017Leerink SwannSet Price TargetBuy$106.00LowView Rating Details
12/4/2017BMO Capital MarketsSet Price TargetHold$84.00LowView Rating Details
11/21/2017Societe GeneraleBoost Price TargetN/AView Rating Details
10/30/2017SunTrust BanksReiterated RatingBuyN/AView Rating Details
10/27/2017Piper Jaffray CompaniesBoost Price TargetOverweight$115.00N/AView Rating Details
10/16/2017Jefferies GroupBoost Price TargetBuy$107.00 -> $115.00N/AView Rating Details
10/13/2017BarclaysBoost Price TargetEqual Weight$90.00N/AView Rating Details
10/11/2017CowenUpgradeMarket Perform -> Outperform$91.17 -> $105.00N/AView Rating Details
10/1/2017Credit Suisse GroupReiterated RatingNeutral$74.00 -> $94.00MediumView Rating Details
9/30/2017Evercore ISIReiterated RatingOutperform$95.00 -> $100.00MediumView Rating Details
9/29/2017ArgusBoost Price TargetBuy$90.00 -> $110.00LowView Rating Details
9/29/2017Morgan StanleyBoost Price TargetEqual Weight$70.00 -> $95.00LowView Rating Details
9/28/2017Deutsche BankBoost Price TargetHold$88.00LowView Rating Details
9/8/2017Goldman Sachs GroupReiterated RatingBuy$85.00 -> $100.00LowView Rating Details
12/8/2016William BlairReiterated RatingOutperform$76.00N/AView Rating Details
11/28/2016CitigroupDowngradeBuy -> Neutral$60.00N/AView Rating Details
9/8/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$75.00 -> $73.00N/AView Rating Details
9/1/2016Raymond James FinancialInitiated CoverageOutperform$82.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$59.00N/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

AbbVie (NYSE:ABBV) Earnings History and Estimates Chart

Earnings by Quarter for AbbVie (NYSE:ABBV)

AbbVie (NYSE ABBV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/25/2018N/AView Earnings Details
10/27/2017Q3 2017$1.39$1.41$7.00 billion$7.00 billionViewN/AView Earnings Details
7/28/2017Q2 2017$1.40$1.42$6.93 billion$6.94 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.26$1.28$6.49 billion$6.54 billionViewN/AView Earnings Details
1/27/2017Q416$1.20$1.20$6.92 billion$6.78 billionViewListenView Earnings Details
10/28/2016Q316$1.21$1.21$6.55 billion$6.43 billionViewListenView Earnings Details
7/29/2016Q216$1.20$1.26$6.20 billion$6.43 billionViewListenView Earnings Details
4/28/2016Q116$1.14$1.15$6.03 billion$5.96 billionViewListenView Earnings Details
1/29/2016Q415$1.12$1.13$6.41 billion$6.36 billionViewListenView Earnings Details
10/30/2015Q315$1.08$1.13$5.90 billion$4.94 billionViewListenView Earnings Details
7/24/2015Q215$1.06$1.08$5.60 billion$5.48 billionViewListenView Earnings Details
4/23/2015Q115$0.85$0.94$718.50 million$5.04 billionViewListenView Earnings Details
1/30/2015Q414$0.86$0.89$5.34 billion$5.45 billionViewListenView Earnings Details
10/31/2014Q3$0.77$0.89$4.82 million$5.02 millionViewListenView Earnings Details
7/25/2014Q214$0.76$0.82$4.70 billion$4.93 billionViewListenView Earnings Details
4/25/2014Q114$0.68$0.71$4.33 billion$4.56 billionViewListenView Earnings Details
1/31/2014Q413$0.82$0.82$5.10 billion$5.11 billionViewListenView Earnings Details
10/25/2013Q313$0.78$0.82$4.52 billion$4.66 billionViewListenView Earnings Details
7/26/2013Q2 2013$0.79$0.92$4.54 billion$4.69 billionViewListenView Earnings Details
4/26/2013Q1 2013$0.67$0.68$4.17 billion$4.33 billionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

AbbVie (NYSE:ABBV) Earnings Estimates

2018 EPS Consensus Estimate: $6.99
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$1.56$1.56$1.56
Q2 20181$1.75$1.75$1.75
Q3 20181$1.79$1.79$1.79
Q4 20181$1.89$1.89$1.89
(Data provided by Zacks Investment Research)

Dividends

AbbVie (NYSE:ABBV) Dividend Information

Next Dividend:2/15/2018
Annual Dividend:$2.56
Dividend Yield:2.66%
Dividend Growth:12.50% (3 Year Average)
Payout Ratio:62.29% (Trailing 12 Months of Earnings)
46.13% (Based on This Year's Estimates)
39.02% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for AbbVie (NYSE:ABBV)

AbbVie (NYSE:ABBV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/27/2017Quarterly$0.713.12%1/11/20181/12/20182/15/2018
9/8/2017Quarterly$0.642.94%10/12/201710/13/201711/15/2017
6/23/2017quarterly$0.643.52%7/12/20177/14/20178/15/2017
2/17/2017quarterly$0.644.14%4/11/20174/13/20175/15/2017
10/28/2016quarterly$0.644.44%1/11/20171/13/20172/15/2017
9/12/2016quarterly$0.573.56%10/12/201610/14/201611/15/2016
6/17/2016quarterly$0.573.8%7/13/20167/15/20168/15/2016
2/19/2016quarterly$0.574.2%4/13/20164/15/20165/16/2016
11/2/2015quarterly$0.573.6%1/13/20161/15/20162/16/2016
9/14/2015quarterly$0.513.46%10/13/201510/15/201511/14/2015
6/19/2015quarterly$0.512.94%7/13/20157/15/20158/14/2015
2/20/2015quarterly$0.513.33%4/13/20154/15/20155/15/2015
10/20/2014quarterly$0.493.48%1/13/20151/15/20152/13/2015
9/19/2014quarterly$0.422.86%10/10/201410/15/201411/17/2014
6/19/2014quarterly$0.423.15%7/11/20147/15/20148/15/2014
2/20/2014quarterly$0.423.29%4/11/20144/15/20145/15/2014
12/12/2013quarterly$0.403.06%1/13/20141/15/20142/14/2014
9/19/2013quarterly$0.403.34%10/10/201310/15/201311/15/2013
6/20/2013quarterly$0.403.75%7/11/20137/15/20138/15/2013
2/15/2013quarterly$0.404.19%4/11/20134/15/20135/15/2013
1/7/2013special$0.401/11/20131/15/20132/15/2013
1/4/2013quarterly$0.401/15/20132/15/2013
(Data available from 1/1/2013 forward)

Insider Trades

AbbVie (NYSE ABBV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 69.32%
Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

AbbVie (NYSE ABBV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/21/2017Richard A GonzalezChairmanSell218,193$94.01$20,512,323.93View SEC Filing  
11/10/2017Michael SeverinoEVPSell25,633$94.69$2,427,188.77View SEC Filing  
10/30/2017Henry O GosebruchInsiderSell18,300$90.55$1,657,065.00View SEC Filing  
9/28/2017Robert A MichaelVPSell6,699$88.00$589,512.00View SEC Filing  
9/11/2017Azita Saleki-GerhardtSVPSell8,300$85.02$705,666.00View SEC Filing  
8/7/2017Richard A GonzalezChairmanSell193,131$71.00$13,712,301.00View SEC Filing  
8/4/2017Richard A GonzalezChairmanSell87,899$71.02$6,242,586.98View SEC Filing  
8/3/2017Richard A GonzalezCEOSell65,861$71.00$4,676,131.00View SEC Filing  
7/31/2017Edward J RappDirectorBuy4,000$70.45$281,800.00View SEC Filing  
7/31/2017Henry O GosebruchInsiderSell18,000$70.09$1,261,620.00View SEC Filing  
6/14/2017Carlos AlbanEVPSell45,800$70.00$3,206,000.00View SEC Filing  
6/14/2017Laura J SchumacherInsiderSell79,800$70.00$5,586,000.00View SEC Filing  
5/19/2017Richard A GonzalezChairmanSell71,235$65.49$4,665,180.15View SEC Filing  
5/18/2017William J ChaseCFOSell38,300$65.35$2,502,905.00View SEC Filing  
5/4/2017Carlos AlbanEVPSell43,000$67.00$2,881,000.00View SEC Filing  
3/10/2017Laura J SchumacherInsiderSell40,000$65.26$2,610,400.00View SEC Filing  
3/10/2017Robert A MichaelVPSell5,132$65.29$335,068.28View SEC Filing  
3/10/2017Timothy J RichmondSVPSell22,451$65.29$1,465,825.79View SEC Filing  
3/8/2017Richard A GonzalezChairmanSell72,016$64.25$4,627,028.00View SEC Filing  
12/2/2016William J ChaseCFOSell6,600$59.19$390,654.00View SEC Filing  
9/7/2016Laura J SchumacherInsiderSell50,000$65.00$3,250,000.00View SEC Filing  
6/24/2016Laura J SchumacherEVPSell186,106$60.03$11,171,943.18View SEC Filing  
6/2/2016Richard A GonzalezCEOSell285,953$63.82$18,249,520.46View SEC Filing  
5/11/2016Richard A GonzalezCEOSell39,000$63.80$2,488,200.00View SEC Filing  
5/10/2016Carlos AlbanEVPSell47,438$63.52$3,013,261.76View SEC Filing  
5/10/2016Thomas A HurwichVPSell6,000$63.59$381,540.00View SEC Filing  
5/10/2016Timothy J RichmondSVPSell21,583$63.52$1,370,952.16View SEC Filing  
3/8/2016Laura J SchumacherEVPSell25,000$56.09$1,402,250.00View SEC Filing  
3/1/2016Timothy J RichmondSVPSell12,866$55.05$708,273.30View SEC Filing  
4/28/2015Richard A GonzalezCEOSell102,964$64.67$6,658,681.88View SEC Filing  
3/2/2015Laura J SchumacherEVPSell25,000$60.30$1,507,500.00View SEC Filing  
3/2/2015Timothy J RichmondSVPSell14,388$60.33$868,028.04View SEC Filing  
12/22/2014William J ChaseCFOSell8,495$68.00$577,660.00View SEC Filing  
3/4/2014Richard GonzalezCEOSell4,799$51.20$245,708.80View SEC Filing  
3/3/2014Azita Saleki-GerhardtSVPSell2,443$50.25$122,760.75View SEC Filing  
3/3/2014Carlos AlbanEVPSell2,882$50.09$144,359.38View SEC Filing  
3/3/2014William ChaseCFOSell3,948$50.22$198,268.56View SEC Filing  
9/17/2013Azita Saleki-GerhardtSVPSell10,473$45.84$480,082.32View SEC Filing  
8/19/2013Azita Saleki-GerhardtSVPSell1,270$43.01$54,622.70View SEC Filing  
8/12/2013Azita Saleki-GerhardtSVPSell8,851$44.91$397,498.41View SEC Filing  
3/11/2013Edward J RappDirectorBuy2,500$37.67$94,175.00View SEC Filing  
2/4/2013Frederick H WaddellDirectorBuy2,000$37.05$74,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AbbVie (NYSE ABBV) News Headlines

Source:
DateHeadline
AbbVie Makes Progress on Quest to DiversifyAbbVie Makes Progress on Quest to Diversify
www.fool.com - December 12 at 10:24 PM
Zacks: Brokerages Anticipate AbbVie Inc (ABBV) to Post $1.43 Earnings Per ShareZacks: Brokerages Anticipate AbbVie Inc (ABBV) to Post $1.43 Earnings Per Share
www.americanbankingnews.com - December 12 at 5:14 PM
IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening ConditionIMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition
finance.yahoo.com - December 11 at 3:13 PM
This Is How To Invest in the Marijuana IndustryThis Is How To Invest in the Marijuana Industry
finance.yahoo.com - December 11 at 3:13 PM
AbbVie (ABBV) a Strong Buy on Top-End Earnings MomentumAbbVie (ABBV) a Strong Buy on Top-End Earnings Momentum
investorplace.com - December 11 at 11:06 AM
Leerink Swann Analysts Give AbbVie (ABBV) a $106.00 Price TargetLeerink Swann Analysts Give AbbVie (ABBV) a $106.00 Price Target
www.americanbankingnews.com - December 10 at 6:28 AM
IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) PatientsIMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients
www.prnewswire.com - December 9 at 10:11 AM
Q2 2018 Earnings Estimate for AbbVie Inc. (ABBV) Issued By Leerink SwannQ2 2018 Earnings Estimate for AbbVie Inc. (ABBV) Issued By Leerink Swann
www.americanbankingnews.com - December 8 at 9:46 AM
AbbVie/J&Js Imbruvica Succeeds in Combo Study with Rituxan - NasdaqAbbVie/J&J's Imbruvica Succeeds in Combo Study with Rituxan - Nasdaq
www.nasdaq.com - December 6 at 3:00 PM
Janssen, AbbVie"s Imbruvica Achieves PFS in Innovate StudyJanssen, AbbVie"s Imbruvica Achieves PFS in Innovate Study
finance.yahoo.com - December 6 at 3:00 PM
Leerink Swann Weighs in on AbbVie Inc.s Q1 2018 Earnings (ABBV)Leerink Swann Weighs in on AbbVie Inc.'s Q1 2018 Earnings (ABBV)
www.americanbankingnews.com - December 6 at 10:16 AM
True Leaf Seeks to Raise Capital as It Prepares to Enter into the Booming Canadian Marijuana MarketTrue Leaf Seeks to Raise Capital as It Prepares to Enter into the Booming Canadian Marijuana Market
finance.yahoo.com - December 5 at 3:07 PM
AbbVies risankizumab successful in fourth late-stage psoriasis study - Seeking AlphaAbbVie's risankizumab successful in fourth late-stage psoriasis study - Seeking Alpha
seekingalpha.com - December 5 at 5:33 AM
AbbVie (ABBV) Given a $84.00 Price Target at BMO Capital MarketsAbbVie (ABBV) Given a $84.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - December 4 at 3:10 PM
AbbVies stock climbs after positive late-stage trial results of psoriasis treatmentAbbVie's stock climbs after positive late-stage trial results of psoriasis treatment
finance.yahoo.com - December 4 at 3:10 PM
Top Biotech Stock Near Buy Zone, Shows Positive Drug Trial ResultsTop Biotech Stock Near Buy Zone, Shows Positive Drug Trial Results
finance.yahoo.com - December 4 at 3:10 PM
AbbVie (ABBV) a Strong Buy on Best-in-Class Quant ScoreAbbVie (ABBV) a Strong Buy on Best-in-Class Quant Score
investorplace.com - December 4 at 11:52 AM
AbbVie Raises Dividend 11%... What Now? - Seeking AlphaAbbVie Raises Dividend 11%... What Now? - Seeking Alpha
seekingalpha.com - December 4 at 5:24 AM
AbbVie Stock Up More Than 30% So Far in 2H17: Heres Why - NasdaqAbbVie Stock Up More Than 30% So Far in 2H17: Here's Why - Nasdaq
www.nasdaq.com - December 1 at 5:19 AM
AbbVie Stock Up More Than 30% So Far in 2H17: Here's WhyAbbVie Stock Up More Than 30% So Far in 2H17: Here's Why
finance.yahoo.com - November 30 at 3:15 PM
Shelton Capital Management Buys DowDuPont Inc, Franklin Resources Inc, AbbVie Inc, Sells SPDR ... - NasdaqShelton Capital Management Buys DowDuPont Inc, Franklin Resources Inc, AbbVie Inc, Sells SPDR ... - Nasdaq
www.nasdaq.com - November 30 at 5:16 AM
How Do Analysts See AbbVie Inc (ABBV) Performing Over The Next Year?How Do Analysts See AbbVie Inc (ABBV) Performing Over The Next Year?
finance.yahoo.com - November 29 at 3:06 PM
Best-in-Class Quant Score Makes AbbVie (ABBV) a Strong Buy - Investorplace.comBest-in-Class Quant Score Makes AbbVie (ABBV) a Strong Buy - Investorplace.com
investorplace.com - November 27 at 3:16 PM
U.S. Supreme Court divided over legality of patent reviewsU.S. Supreme Court divided over legality of patent reviews
finance.yahoo.com - November 27 at 3:16 PM
AbbVie Inc. (ABBV) Expected to Announce Quarterly Sales of $7.56 BillionAbbVie Inc. (ABBV) Expected to Announce Quarterly Sales of $7.56 Billion
www.americanbankingnews.com - November 26 at 2:50 AM
GSB Wealth Management, LLC Buys DNP Select Income Fund, DNP Select Income Fund, DowDuPont Inc, ...GSB Wealth Management, LLC Buys DNP Select Income Fund, DNP Select Income Fund, DowDuPont Inc, ...
www.nasdaq.com - November 25 at 3:18 PM
Abbvie Inc (ABBV) Chairman of the Board and CEO Richard A Gonzalez Sold $20.5 million of SharesAbbvie Inc (ABBV) Chairman of the Board and CEO Richard A Gonzalez Sold $20.5 million of Shares
finance.yahoo.com - November 25 at 6:43 AM
AbbVie Inc. (ABBV) Expected to Announce Earnings of $1.43 Per ShareAbbVie Inc. (ABBV) Expected to Announce Earnings of $1.43 Per Share
www.americanbankingnews.com - November 24 at 9:08 PM
AbbVie Inc. (ABBV) Chairman Richard A. Gonzalez Sells 218,193 SharesAbbVie Inc. (ABBV) Chairman Richard A. Gonzalez Sells 218,193 Shares
www.americanbankingnews.com - November 24 at 7:27 PM
AbbVie Inc. (ABBV) Receives Consensus Recommendation of "Buy" from AnalystsAbbVie Inc. (ABBV) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 23 at 7:56 PM
AbbVies (ABBV) "Hold" Rating Reiterated at BMO Capital MarketsAbbVie's (ABBV) "Hold" Rating Reiterated at BMO Capital Markets
www.americanbankingnews.com - November 22 at 1:44 PM
AbbVie (ABBV) Says Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at ASHAbbVie (ABBV) Says Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at ASH
www.streetinsider.com - November 21 at 8:55 PM
AbbVie Inc. (ABBV) PT Raised to $0.00AbbVie Inc. (ABBV) PT Raised to $0.00
www.americanbankingnews.com - November 21 at 8:14 PM
Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition, Highlighting AbbVies Commitment to Helping Blood Cancer PatientsPhase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition, Highlighting AbbVie's Commitment to Helping Blood Cancer Patients
finance.yahoo.com - November 21 at 3:55 PM
Better Buy: AbbVie Inc. vs. Johnson & JohnsonBetter Buy: AbbVie Inc. vs. Johnson & Johnson
www.fool.com - November 21 at 9:42 AM
Enanta Pharmaceuticals Reports Financial Results for its Fourth Quarter and Year Ended September 30, 2017Enanta Pharmaceuticals Reports Financial Results for its Fourth Quarter and Year Ended September 30, 2017
www.businesswire.com - November 20 at 4:56 PM
ETFs with exposure to AbbVie, Inc. : November 20, 2017ETFs with exposure to AbbVie, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 4:56 PM
High-Level Measures for Earnings Momentum Keep AbbVie (ABBV) a Strong BuyHigh-Level Measures for Earnings Momentum Keep AbbVie (ABBV) a Strong Buy
investorplace.com - November 20 at 11:19 AM
AbbVie Target of Unusually High Options Trading (ABBV)AbbVie Target of Unusually High Options Trading (ABBV)
www.americanbankingnews.com - November 18 at 3:56 AM
Roche's (RHHBY) Hemophilia A Drug Receives FDA ApprovalRoche's (RHHBY) Hemophilia A Drug Receives FDA Approval
finance.yahoo.com - November 17 at 11:04 AM
AbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive ConferenceAbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
finance.yahoo.com - November 16 at 10:34 AM
AbbVie Inc. (ABBV) Receives Hold Rating from BMO Capital MarketsAbbVie Inc. (ABBV) Receives Hold Rating from BMO Capital Markets
www.americanbankingnews.com - November 15 at 11:36 PM
3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock 3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock
www.fool.com - November 15 at 9:22 PM
Tiaa Cref Investment Management Llc Buys DowDuPont Inc, Costco Wholesale Corp, AbbVie Inc, ... - NasdaqTiaa Cref Investment Management Llc Buys DowDuPont Inc, Costco Wholesale Corp, AbbVie Inc, ... - Nasdaq
www.nasdaq.com - November 14 at 3:25 PM
Novartis (NVS) Arm's Biosimilars Study Results EncourageNovartis (NVS) Arm's Biosimilars Study Results Encourage
finance.yahoo.com - November 14 at 3:25 PM
Understanding Sanofi’s Revenues by Segment in 3Q17Understanding Sanofi’s Revenues by Segment in 3Q17
finance.yahoo.com - November 14 at 3:25 PM
Amgen Gets Positive CHMP Opinion to Expand Nplate's LabelAmgen Gets Positive CHMP Opinion to Expand Nplate's Label
finance.yahoo.com - November 13 at 6:04 PM
AbbVie Inc. (ABBV) EVP Sells $2,427,188.77 in StockAbbVie Inc. (ABBV) EVP Sells $2,427,188.77 in Stock
www.americanbankingnews.com - November 13 at 5:43 PM
Earnings Momentum Analytics Power AbbVie (ABBV) to Strong BuyEarnings Momentum Analytics Power AbbVie (ABBV) to Strong Buy
investorplace.com - November 13 at 11:17 AM
AbbVie Inc. (ABBV) Stock Rating Upgraded by BidaskClubAbbVie Inc. (ABBV) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - November 11 at 2:20 PM

SEC Filings

AbbVie (NYSE:ABBV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AbbVie (NYSE:ABBV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AbbVie (NYSE ABBV) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.